睿知中国疾病研究地图
候选清单0

正在招募胃癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06158919,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Patients with unresectable advanced or metastatic gastric/esophagogastric junction adenocarcinoma confirmed by pathology or histology;

    入选标准第 2 条

  3. Have not received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) for unresectable advanced or metastatic gastric cancer; If you have received adjuvant therapy after radical gastrectomy of gastric cancer, it is required that the time between the discovery of metastatic disease and the end of the last adjuvant chemotherapy is greater than 6 months);

    入选标准第 4 条

    Had other malignancies within 5 years prior to admission, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;

    排除标准第 2 条

  4. Absolute neutrophil count ≥1.5×109/L, white blood cell ≥3.0×109/L;

    入选标准第 7 条

    Platelet ≥90×109/L;

    入选标准第 8 条

    Hemoglobin ≥8g/dL;

    入选标准第 9 条

    Total bilirubin TBIL≤1.5 times ULN;

    入选标准第 10 条

  5. Must have at least one measurable lesion (meet the RECIST v1.1 standard);

    入选标准第 5 条

  6. Premenopausal and postmenopausal women \< Women of 1 year must have a negative serum or urine pregnancy test before treatment.

    入选标准第 11 条

    Women who are pregnant (positive pregnancy test before medication) or breastfeeding;

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06158919,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Have fully understood the study and voluntarily signed the informed consent;
  2. Patients with unresectable advanced or metastatic gastric/esophagogastric junction adenocarcinoma confirmed by pathology or histology;
  3. Expected survival ≥3 months;
  4. Have not received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) for unresectable advanced or metastatic gastric cancer; If you have received adjuvant therapy after radical gastrectomy of gastric cancer, it is required that the time between the discovery of metastatic disease and the end of the last adjuvant chemotherapy is greater than 6 months);
  5. Must have at least one measurable lesion (meet the RECIST v1.1 standard);
  6. The functions of vital organs meet the following requirements (the use of any blood components and cell growth factors is not allowed within the first 14 days of enrollment) :
  7. Absolute neutrophil count ≥1.5×109/L, white blood cell ≥3.0×109/L;
  8. Platelet ≥90×109/L;
  9. Hemoglobin ≥8g/dL;
  10. Total bilirubin TBIL≤1.5 times ULN;
  11. Premenopausal and postmenopausal women \< Women of 1 year must have a negative serum or urine pregnancy test before treatment.

排除标准:Exclusion Criteria:

  1. 1. Patients with known HER-2 status (immunohistochemical 3+, or immunohistochemical 2+\&FISH positive);
  2. Had other malignancies within 5 years prior to admission, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
  3. Previously received allogeneic bone marrow transplantation or organ transplantation;
  4. Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, in the 6 months prior to enrollment;
  5. Subjects who are allergic to the investigational drug or any of its adjuncts;
  6. Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg;
  7. Had any disease or condition affecting drug absorption before enrollment, or the patient could not take drugs orally;
  8. Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unexcised tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;
  9. Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks >5 mL of fresh blood) or had a thromboembolic event (including stroke events and/or transient ischemic attacks) within 12 months;
  10. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50%;
  11. Active or uncontrolled severe infection (≥CTCAE v5.0 grade 2 infection);
  12. Known human immunodeficiency virus (HIV) infection. Known history of clinically significant liver disease, including viral hepatitis [Known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., positive HBV DNA (≥1×104 copies /mL or >2000 IU/ mL); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL);
  13. The patient has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; The patient had vitiligo; Those with complete remission of asthma in childhood can be included without any intervention in adulthood; Patients with asthma requiring medical intervention with bronchodilators are not included); Replacement therapy is not considered systemic, and the following patients may be included: have a history of autoimmune related hypothyroidism and are receiving thyroid hormone replacement therapy; Type 1 diabetes can be controlled by insulin therapy.
  14. Immunosuppressive use of immunosuppressants or systemic hormone therapy within 7 days prior to enrollment for immunosuppressive purposes (dose >10mg/ day prednisone or other therapeutic hormone).
  15. Currently suffering from interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, radiation pneumonia;
  16. Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
  17. Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk;
  18. Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume ≥1.0g;

引自 ClinicalTrials.gov, NCT06158919, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06158919,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06158919